Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy
PLOS Pathogens · 11.09.2025 · 21 (9) · e1013466
DOI: 10.1371/journal.ppat.1013466 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 11.09.2025. Verfasst von Maria C Puertas und 9 weiteren Autor:innen. Beteiligte Einrichtung: IrsiCaixa, Badalona, Barcelona, Spain. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Proviruses, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, ViiV Healthcare, Fundació Lluita contra les Infeccions.
Abstract (Originalsprache)
Despite its efficacy, antiretroviral therapy (ART) is not curative, and HIV-1 rebound occurs whenever treatment is interrupted. The viral reservoir in latently infected cells is the source of the infection resurgence, making it crucial to understand when and how this reservoir is established so that it can be targeted more effectively. In this study, we evaluated the decay dynamics of proviral DNA in 40 ART-naive people initiating dolutegravir-based treatment and compared these dynamics to the decay kinetics of inducible proviruses, as measured using the VIP-SPOT assay. Intensive sampling during the first month, followed by regular sampling up to 48 weeks, enabled us to outline the biphasic decay dynamics of different fractions of the viral reservoir. Our results show that the first decay phase of inducible proviruses is significantly faster than that of total HIV-1 DNA (2.6 days versus 5.1 weeks), indicating that selective pressure on this specific fraction of proviruses is particularly effective during the first days after ART initiation. These findings suggest that therapeutic interventions aimed at impacting the viral reservoir by boosting the immune response targeting the inducible fraction should be implemented at the time of, or immediately before, treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IrsiCaixa, Badalona, Barcelona, Spain.
- Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain.
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
- Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
- Fundació Lluita contra les Infeccions, Badalona, Spain.
- Projecte dels NOMS-Hispanosida, BCN CheckPoint, Barcelona, Spain.
ORCID-Profile: Maria C Puertas, Javier Martinez-Picado
Förderung
- NIAID NIH HHS
- ViiV Healthcare
- Fundació Lluita contra les Infeccions
- NIH/NIAID
- Generalitat de Catalunya
Zitieren
APA
Puertas, M. C., Bailón, L., Urrea, V., García-Guerrero, M. C., Alarcón-Soto, Y., Rivero, A., Mothe, B., Moltó, J., Martinez-Picado, J., & DUALITY study group (2025). Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy. PLOS Pathogens, 21(9), e1013466. https://doi.org/10.1371/journal.ppat.1013466
Vancouver
Puertas MC, Bailón L, Urrea V, García-Guerrero MC, Alarcón-Soto Y, Rivero A, et al. Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy. PLOS Pathogens. 2025;21(9):e1013466. doi:10.1371/journal.ppat.1013466
BibTeX
@article{Puertas2025,
author = {Puertas, Maria C and Bailón, Lucía and Urrea, Víctor and García-Guerrero, Maria C and Alarcón-Soto, Yovaninna and Rivero, Angel and Mothe, Beatriz and Moltó, José and Martinez-Picado, Javier and DUALITY study group, DUALITY study group},
title = {Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {9},
pages = {e1013466},
doi = {10.1371/journal.ppat.1013466}
}
EUVIMED